TABLE 1.
Summary of studies included in the systematic review (N = 47).
| Study ID (author and year) | Country of study | Study type | Study setting | Inclusion of HSCT patients | Age of participants (years), mean (range) | Ethnicity (non‐White%) | Sex (% male) | Type of cancer | Total no. of participants in study | Person reporting fatigue | Fatigue prevalence reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gandy et al. 2022 [20] | USA | Prospective cohort | NR | No | 8.3 (3–16) | 54.5 | 57.6 | CNS tumor | 37 | Parent | Yes |
| Irestorm et al. 2022 [21] | Netherlands | Prospective cohort | NR | NR | 6.3 (NR) | NR | 56.5 | ALL | 127 | Parent | Yes |
| Jacobs et al. 2022 [22] | USA and Canada | Prospective cohort | Both | NR | 13.0 (7–18) | 22.2 | 51.4 | LL | 257 | Patient | Yes |
| Weaver et al. 2022 [23] | USA | Prospective cohort | Both | No | 13.0 (7–17) | 43.5 | 54.7 | Mixed a | 492 | Patient | Yes |
| Wu et al. 2022 [24] | China | Cross‐sectional | Both | NR | 8.9 (NR) | NR | 60.0 | Mixed a | 40 | Patient | No |
| Bradford et al. 2021 [25] | Australia | Cross‐sectional | Outpatient | No | 12 (8–18) | NR | 69.0 | Mixed a | 48 | Patient | Yes |
| Cheng et al. 2021 [26] | China | Cross‐sectional | Both | NR | NR | 100.0 | 66.8 | Mixed a | 187 | Patient | Yes |
| Cheng KK et al. 2021 [27] | Singapore | Prospective cohort | Outpatient | Yes | 13.7 (10–18) | NR | 62.0 | Mixed a | 50 | Patient | Yes |
| Brown et al. 2021 [28] | USA | Cross‐sectional | NR | NR | 8.5 (2.6–17.3) | 75.0 | 56.0 | ALL | 171 | Parent and patient | No |
| Daniel et al. 2020 [29] | USA | Cross‐sectional | Outpatient | NR | 10.1 (5–17) | 24.5 | 44.4 | Mixed a | 59 | Patient | No |
| Li et al. 2020 [30] | China | Cross‐sectional | Both | No | 8.9 (NR) | NR | 61.0 | ALL and AML | 159 | Parent and patient | Yes |
| Rostagno et al. 2020 [31] | Italy | Prospective cohort | Both | NR | 11.7 (5–17) | NR | 54.5 | Mixed a | 134 | Parent and patient | Yes |
| Steur et al. 2020 [32] | Netherlands | Prospective cohort | Outpatient | NR | (1–19) | NR | 57.0 | ALL | 151 | Parent | No |
| Cadamuro et al. 2020 [33] | Brazil | Cross‐sectional | Both | Yes | NR | 52.2 | 49.7 | Mixed a | 157 | Parent and patient | Yes |
| Kudubes et al. 2019 [34] | Turkey | Phase 3 RCT | Inpatient | NR | 9.4/9.1 (control and experimental group, NR) | NR | 57.5 | Mixed a | 80 | Parent and patient | Yes |
| Nagarajan et al. 2019 [35] | USA and Canada | Prospective cohort | Both | No | (2–18) | 17.0 | 52.6 | AML | 560 | Parent and patient | No |
| Rogers et al. 2019 [36] | USA | Phase 3 RCT | Inpatient | Yes | 9.5 (4–19) | 18.2 | 60.6 | Medulloblastoma | 43 | Parent and patient | Yes |
| Tomlinson et al. 2019 [8] | USA and Canada | Cross‐sectional | Both | Yes | NR | NR | 61.3 | Mixed a | 366 b | Patient | No |
| Hockenberry et al. 2018 [65] | USA | Prospective cohort | Both | NR | NR | 59.1 | 55.9 | ALL | 191 | Parent and patient | No |
| Macpherson et al. 2018 [37] | USA | Prospective cohort | Both | No | (8–18) | 56.3 | 54.1 | Mixed a | 96 | Patient | Yes |
| Dobrozsi et al. 2017 [38] | USA | Prospective cohort | Both | NR | 11.7 (5–21) | 28.0 | 58.0 | Mixed a | 41 | Patient | No |
| Rodgers et al. 2016 [39] | USA | Prospective cohort | NR | NR | (3–12) | 47.0 | 45.0 | ALL | 38 | Parent and patient | No |
| Bastani et al. 2015 [40] | Iran | Phase 3 RCT | Inpatient | NR | 10.0 (8–12) | NR | 68.3 | ALL | 120 | Patient | Yes |
| Crabtree et al. 2015 [41] | USA | Prospective cohort | NR | NR | 7.7 (2–18) | 19.0 | 51.0 | Mixed a | 170 | Parent and patient | No |
| MDR Nunes et al. 2015 [42] | USA | Descriptive with repeated measures | Outpatient | No | 12.8 (8–17) | 65.7 | 48.6 | Mixed a | 42 | Patient | Yes |
| Rogers et al. 2014 [43] | USA and Canada | Prospective cohort | Outpatient | NR | 8.8 (5–18) | 18.3 | 65.5 | ALL | 100 | Parent and patient | No |
| Ameringer et al. 2013 [44] | USA | Prospective cohort | Both | NR | 15.3 (13–18) | 66.7 | 55.6 | Mixed a | 9 | Patient | Yes |
| Hinds et al. 2013 [45] | USA | Cross‐sectional | Both | NR | 12.9 (8–17) | NR | 55.5 | Mixed a | 93 | Patient | Yes |
| Wesley et al. 2013 [46] | USA | Cross‐sectional | Both | NR | 15.6 (13–19) | 38.0 | 54.9 | NR | 123 | Patient | No |
| Hooke et al. 2011 [47] | USA | Prospective cohort | NR | NR | (6–17) | NR | 66.7 | Mixed a | 30 | Patient | No |
| Miller et al. 2011 [48] | USA | Prospective cohort | Inpatient | NR | 13.5 (10–17) | 59.0 | 43.6 | Mixed | 39 | Patient | Yes |
| Baggott et al. 2010 [5] | USA | Prospective cohort | Both | NR | 14.8 (10–18) | NR | 51.5 | Mixed a | 66 | Patient | Yes |
| Dupuis et al. 2010 [49] | Canada | Cross‐sectional | Both | NR | 9.4 (4–18) | NR | 55.0 | Mixed a | 200 | Parent | Yes |
| Erickson et al. 2010 [50] | USA | Prospective cohort | NR | NR | 16.1 (12–19) | 15.0 | 50.0 | Mixed | 20 | Patient | Yes |
| Hockenberry et al. 2010 [51] | USA | Prospective cohort | Both | NR | (7–18) | 52.0 | 57.0 | Mixed a | 67 | Parent and patient | No |
| Walker et al. 2010 [6] | USA | Prospective cohort | Both | NR | 14.2 (10–19) | 25.0 | 56.9 | Mixed a | 51 | Patient | Yes |
| Zupanec et al. 2010 [52] | Canada | Cross‐sectional | Outpatient | NR | (4–18) | 48.4 | 79.7 | ALL | 77 | Parent and patient | No |
| Sitaresmi et al. 2009 [53] | Indonesia | Prospective cohort | Both | NR | 7.1 (2–16) | NR | 63.0 | ALL | 51 | Parent | Yes |
| Yeh et al. 2009 [54] | Taiwan | Prospective cohort | Both | NR | 14.2 (10–18.9) | NR | 58.0 | Mixed a | 144 | Patient | Yes |
| Ekti Genc et al. 2008 [55] | Turkey | Phase 3 RCT | Inpatient | NR | 9 (7–12) | NR | 61.7 | ALL and AML | 60 | Parent and patient | No |
| Enskar et al. 2008 [56] | Sweden | Cross‐sectional | Both | No | 9.6 (NR) | NR | 59.0 | Mixed | 17 | Patient | Yes |
| Perdikaris et al. 2008 [57] | Greece | Prospective cohort | NR | NR | 8.9 (7–12) | NR | 65.0 | Mixed a | 40 | NR | No |
| Whitsett et al. 2008 [58] | USA and Canada | Prospective cohort | Inpatient | NR | 13.7 (9–17) | 8.3 | 66.7 | Mixed | 12 | Parent and patient | No |
| Yeh et al. 2008 [59] | Taiwan | Prospective cohort | Inpatient | NR | 11.5 (7–17) | NR | 54 | Mixed a | 48 | Parent and patient | No |
| Hinds et al. 2007 [60] | USA | Prospective cohort | Inpatient | NR | 12.5 (7–18) | 28.0 | 41.0 | Mixed a | 29 | Parent, patient and healthcare provider | No |
| Hinds et al. 2007 [61] (cancer journal paper) | USA and Canada | Prospective cohort | Outpatient | NR | (5–18) | 21.0 | 62.0 | ALL | 100 | Parent and patient | No |
| Williams et al. 2006 [62] | USA | Cross‐sectional | Inpatient | No | 10.4 (2–18) | 9.0 | 45.0 | Mixed a | 11 | Patient | Yes |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CNS, central nervous system; HCT, hematopoietic stem cell transplant; LL, leukemia and lymphoma; NR, not‐reported; USA, United States of America.
a
Mixed: mixed cancer types defined as a category where more than two types of patients with cancer were included.
b
Study enrolled 502 patients, of which, 366 were on treatment.